전립선암 치료제 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별 및 용도별, 지역별 인사이트와 예측(2024-2032년)

Growth Factors of prostate cancer therapeutics Market

The global prostate cancer therapeutics market is expanding rapidly as the prevalence of prostate cancer continues to rise and advanced treatment options become more accessible. According to the latest industry assessment, the market was valued at USD 19.81 billion in 2024, is projected to reach USD 25.12 billion in 2025, and is expected to surge to USD 101.98 billion by 2032, registering a robust CAGR of 22.16% during the forecast period. The sharp increase reflects accelerated adoption of targeted therapies, radiopharmaceuticals, immunotherapies, and next-generation androgen receptor inhibitors worldwide.

Market Overview and Regional Leadership

In 2024, North America dominated the global market with a 50.98% share, driven by a high prostate cancer burden, strong healthcare infrastructure, early therapy adoption, and extensive availability of innovative treatment options. The U.S. remains the largest and most influential market owing to the rising incidence of prostate cancer, supportive reimbursement policies, and a strong presence of pharmaceutical companies introducing breakthrough therapies.

Prostate cancer predominantly affects older men, with 6 in 10 diagnoses occurring in individuals aged 65 and above, according to the American Cancer Society. The median age of diagnosis is around 67, and as the global geriatric population grows, treatment demand is increasing sharply. Rising awareness initiatives such as the annual Movember campaign further support early diagnosis and timely therapeutic intervention.

Market Growth Drivers

The rising global prevalence of prostate cancer is a major growth catalyst. GLOBOCAN 2022 reported approximately 1.47 million new cases, ranking prostate cancer as the fourth most prevalent cancer worldwide. Increased screening rates, public health awareness, and improved diagnostic technologies contribute to the expanding patient pool.

Technological advancements also play a key role. Pharmaceutical leaders including Pfizer, Astellas, Johnson & Johnson, Sanofi, AstraZeneca, and AbbVie are continually investing in next-generation therapies, combination regimens, and personalized medicine. The development of PARP inhibitors, androgen receptor inhibitors, and radioligand therapies is reshaping treatment guidelines and improving survival outcomes.

Market Restraints

Despite strong growth prospects, the market faces challenges. Resistance to androgen deprivation therapy-caused by androgen receptor mutations-remains a significant barrier, often leading to Castration-Resistant Prostate Cancer (CRPC). Additionally, common side effects of hormonal and chemotherapies, such as decreased libido, hot flashes, reduced bone density, fatigue, and weight gain, hinder patient adherence and impact treatment continuity.

The high cost of advanced therapies further restricts adoption, particularly in low- and middle-income regions where reimbursement systems are limited. Complex treatment regimens and long-term medication requirements also elevate overall healthcare expenditures.

Emerging Market Opportunities

Research and development activities are accelerating, particularly in the field of combination therapies for managing metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors combined with hormonal therapies are showing enhanced efficacy and gaining regulatory approval. In November 2024, Bayer's NUBEQA received FDA acceptance for use with ADT in metastatic hormone-sensitive prostate cancer (mHSPC), signaling expanding opportunities for combination regimens.

Innovative therapies targeting genetic mutations, including BRCA1 and BRCA2, are gaining traction. For example, Johnson & Johnson's AKEEGA, approved in 2023 for BRCA-mutated mCRPC, reflects the growing emphasis on precision oncology.

Segmental Insights

Androgen receptor inhibitors dominated the market in 2024 with a 73.1% share, supported by rising adoption for first-line treatment in advanced prostate cancer.

The oral route of administration led the market with strong patient preference and is set to capture 86.7% of the market in 2025.

By therapy, hormonal therapy remains the leading segment due to its effectiveness in controlling androgen-dependent tumor growth.

By disease state, mCRPC accounted for the dominant share, expected to capture 83.7% of the market in 2025, due to high clinical need and frequent regulatory approvals for targeted therapies.

Regional Outlook

• North America: Strongest market; expected to reach USD 12.32 billion in 2025.
• Europe: Projected to reach USD 5.89 billion in 2025, supported by strong drug availability and clinical advancements.
• Asia Pacific: Expected to reach USD 4.48 billion in 2025, driven by increased cancer awareness and expanding access to oncology treatments.
• Latin America & Middle East: Steady growth with increased awareness and improving regulatory landscapes.

Conclusion

With its market size rising from USD 19.81 billion in 2024 to a projected USD 101.98 billion by 2032, the prostate cancer therapeutics market is undergoing transformative expansion. The rapid integration of precision medicines, combination therapies, and immunotherapies-coupled with increasing disease prevalence-will continue to drive substantial growth through 2032.

Segmentation By Drug Class

• Androgen Receptor Inhibitors
• Microtubule Inhibitors
• Gonadotropin Releasing Hormone (GnRH) Agonist
• Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
• Others

By Route of Administration

• Oral
• Parenteral

By Therapy

• Chemotherapy
• Hormonal Therapy
• Targeted therapy
• Immunotherapy

By Disease State

• Metastatic Castration-Resistant Prostate Cancer
• Non-Metastatic Castration-Resistant Prostate Cancer

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
• 4.2. Pipeline Analysis, by Key Players
• 4.3. Overview of Alternative Therapies
• 4.4. Key Start-ups in the Market
• 4.5. New Product Launches, by Key Players
• 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.7. Impact of COVID-19 on the Market

5. Global Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Androgen Receptor Inhibitors
  • 5.1.2. Microtubule Inhibitors
  • 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Parenteral
• 5.3. Market Analysis, Insights and Forecast - By Therapy
  • 5.3.1. Chemotherapy
  • 5.3.2. Hormonal Therapy
  • 5.3.3. Targeted therapy
  • 5.3.4. Immunotherapy
• 5.4. Market Analysis, Insights and Forecast - By Disease State
  • 5.4.1. Metastatic Castration-Resistant Prostate Cancer
  • 5.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacies
  • 5.5.2. Drug Stores & Retail Pharmacies
  • 5.5.3. Online Pharmacies
• 5.6. Market Analysis, Insights and Forecast - Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Androgen Receptor Inhibitors
  • 6.1.2. Microtubule Inhibitors
  • 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Parenteral
• 6.3. Market Analysis, Insights and Forecast - By Therapy
  • 6.3.1. Chemotherapy
  • 6.3.2. Hormonal Therapy
  • 6.3.3. Targeted therapy
  • 6.3.4. Immunotherapy
• 6.4. Market Analysis, Insights and Forecast - By Disease State
  • 6.4.1. Metastatic Castration-Resistant Prostate Cancer
  • 6.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital Pharmacies
  • 6.5.2. Drug Stores & Retail Pharmacies
  • 6.5.3. Online Pharmacies
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Androgen Receptor Inhibitors
  • 7.1.2. Microtubule Inhibitors
  • 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
• 7.3. Market Analysis, Insights and Forecast - By Therapy
  • 7.3.1. Chemotherapy
  • 7.3.2. Hormonal Therapy
  • 7.3.3. Targeted therapy
  • 7.3.4. Immunotherapy
• 7.4. Market Analysis, Insights and Forecast - By Disease State
  • 7.4.1. Metastatic Castration-Resistant Prostate Cancer
  • 7.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital Pharmacies
  • 7.5.2. Drug Stores & Retail Pharmacies
  • 7.5.3. Online Pharmacies
• 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.6.1. Germany
  • 7.6.2. U.K.
  • 7.6.3. France
  • 7.6.4. Italy
  • 7.6.5. Spain
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Androgen Receptor Inhibitors
  • 8.1.2. Microtubule Inhibitors
  • 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Parenteral
• 8.3. Market Analysis, Insights and Forecast - By Therapy
  • 8.3.1. Chemotherapy
  • 8.3.2. Hormonal Therapy
  • 8.3.3. Targeted therapy
  • 8.3.4. Immunotherapy
• 8.4. Market Analysis, Insights and Forecast - By Disease State
  • 8.4.1. Metastatic Castration-Resistant Prostate Cancer
  • 8.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital Pharmacies
  • 8.5.2. Drug Stores & Retail Pharmacies
  • 8.5.3. Online Pharmacies
• 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Androgen Receptor Inhibitors
  • 9.1.2. Microtubule Inhibitors
  • 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Parenteral
• 9.3. Market Analysis, Insights and Forecast - By Therapy
  • 9.3.1. Chemotherapy
  • 9.3.2. Hormonal Therapy
  • 9.3.3. Targeted therapy
  • 9.3.4. Immunotherapy
• 9.4. Market Analysis, Insights and Forecast - By Disease State
  • 9.4.1. Metastatic Castration-Resistant Prostate Cancer
  • 9.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital Pharmacies
  • 9.5.2. Drug Stores & Retail Pharmacies
  • 9.5.3. Online Pharmacies
• 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Androgen Receptor Inhibitors
  • 10.1.2. Microtubule Inhibitors
  • 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Parenteral
• 10.3. Market Analysis, Insights and Forecast - By Therapy
  • 10.3.1. Chemotherapy
  • 10.3.2. Hormonal Therapy
  • 10.3.3. Targeted therapy
  • 10.3.4. Immunotherapy
• 10.4. Market Analysis, Insights and Forecast - By Disease State
  • 10.4.1. Metastatic Castration-Resistant Prostate Cancer
  • 10.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Drug Stores & Retail Pharmacies
  • 10.5.3. Online Pharmacies
• 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. Astellas Pharma Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Pfizer Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Johnson & Johnson Services, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Sanofi
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Ferring Pharmaceuticals Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. AbbVie Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. AstraZeneca
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Tolmar, Inc.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Dendreon Pharmaceuticals LLC.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Bayer AG
    • 11.2.11.1. Overview
    • 11.2.11.2. Products
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)